Clinical trial
Deposition of Inhaled Prolastin in Cystic Fibrosis Patients
NCT00486837 · Grifols Therapeutics LLC, Industry · Completed
Key facts
| NCT number | NCT00486837 |
|---|---|
| Title | Deposition of Inhaled Prolastin in Cystic Fibrosis Patients |
| Official title | Multicenter, Randomized, Parallel Group Study to Investigate the Optimal Deposition Site for Inhaled Prolastin® in Patients With Cystic Fibrosis (CF) |
| Acronym | CF2 |
| Lead sponsor | Grifols Therapeutics LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Alpha1-Proteinase Inhibitor (Human) |
| Enrollment | 72 |
| Start date | Dec 1, 2003 |
| Primary completion | Jun 1, 2004 |
| Completion | Jun 1, 2004 |
| First posted | Jun 15, 2007 |
| Last update posted | Aug 21, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: